Literature DB >> 15944939

Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.

J Thiele1, H M Kvasnicka, H Dietrich, G Stein, M Hann, A Kaminski, N Rathjen, K A Metz, D W Beelen, M Ditschkowski, A Zander, N Kroeger.   

Abstract

Scant knowledge exists about the dynamics of fibro-osteosclerotic bone marrow (BM) lesions and regeneration of hematopoiesis following allogeneic peripheral stem cell transplantation (SCT) in chronic idiopathic myelofibrosis. Therefore, an immunohistochemical and morphometric study was performed on BM biopsies in 20 patients before and at standardized intervals (days 30 through 384) following SCT. In responding patients, a total regression of the pretransplant increased fibrosis was completed in the posttransplant period after about six months, while the extent of osteosclerosis did not change significantly during observation time. The quantity of CD61+ megakaryocytes including precursors was strikingly variable after SCT and, by using planimetric methods, atypical microforms exhibiting a dysplastic aspect could be demonstrated. These anomalies may be responsible for posttransplant thrombocytopenia. CD34+ progenitor cells were increased before transplantation, however, their number declined rapidly to normal values in responding patients. Nucleated erythroid precursors revealed a decreased amount before and after SCT accounting for anemia. Large clusters of this cell lineage indicated an initial hematopoietic reconstitution comparable with the expansion of the neutrophil granulopoiesis. Proliferative activity and apoptosis showed an increase until one year after SCT that implied a still regenerating hematopoiesis in keeping with an enhanced cell turnover.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944939     DOI: 10.14670/HH-20.879

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  19 in total

Review 1.  Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Authors:  Vikas Gupta; Jason Gotlib; Jerald P Radich; Nicolaus M Kröger; Damiano Rondelli; Srdan Verstovsek; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

Review 2.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 3.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

4.  Myelofibrosis osteoclasts are clonal and functionally impaired.

Authors:  Ivo Veletic; Taghi Manshouri; Asha S Multani; C Cameron Yin; Lei Chen; Srdan Verstovsek; Zeev Estrov
Journal:  Blood       Date:  2019-02-11       Impact factor: 22.113

5.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 6.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 7.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

Review 8.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 9.  Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.

Authors:  Aziz Nazha; Joseph D Khoury; Raajit K Rampal; Naval Daver
Journal:  Oncologist       Date:  2015-08-24

10.  Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.

Authors:  Nicolaus Kröger; Michael Kvasnicka; Jürgen Thiele
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.